[144] Axsome Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) Form 144 shows a proposed sale of 20,000 common shares through Charles Schwab & Co., Inc. for an aggregate market value of $2,425,335.00 with an approximate sale date of 08/29/2025 on NASDAQ. The filer reports acquiring the 20,000 shares on 03/19/2019 by exercise and hold from Axsome Therapeutics, Inc., with payment in cash.

The filing also discloses sales by the same person during the past three months: 16,694 shares on 08/22/2025 (gross proceeds $2,004,598.00), and three separate sales of 20,000 shares on 08/26/2025, 08/27/2025, and 08/28/2025 with gross proceeds of $2,400,658.00, $2,446,052.00, and $2,432,004.00 respectively. The filing states total shares outstanding of 49,901,487.

Positive

• None.

Negative

• Proposed sale of 20,000 common shares valued at $2,425,335.00 to be sold on 08/29/2025 on NASDAQ.
• Recent sales by the same person in the past three months total 76,694 shares for gross proceeds of approximately $9,283,312.00 (dates: 08/22/2025–08/28/2025).

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing sizable recent disposals but no new company disclosures.

The Form 144 is a standard notice of intended resale under Rule 144. It documents a proposed 20,000-share sale valued at $2.43M and lists multiple recent sales totaling 76,694 shares with gross proceeds of about $9.28M. This is a disclosure of selling activity, not an operational update; it does not provide new financial or strategic information about Axsome. For investors, the filing increases transparency about insider share movements but contains no statements about company performance or material nonpublic information.

Corporate Governance Expert

TL;DR: Compliance filing indicates insider liquidity events; no allegations of undisclosed material information.

The filer affirms under signature language that they are unaware of material nonpublic information. The filing shows shares were acquired by exercise in 2019 and are being sold through a broker, which follows standard Rule 144 procedures. From a governance perspective, the record of multiple sales within a short window merits monitoring for timing and pattern, but the document itself is procedural and contains no governance violations or 10b5-1 plan disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	2425335.00	49901487	08/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/19/2019	Exercise and Hold	Axsome Therapeutics, Inc.			20000	03/19/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/22/2025	16694	2004598.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/26/2025	20000	2400658.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/27/2025	20000	2446052.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/28/2025	20000	2432004.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Axsome (AXSM) Form 144 report?

The Form 144 reports a proposed sale of 20,000 common shares valued at $2,425,335.00 with an approximate sale date of 08/29/2025 on NASDAQ.

Who is the broker handling the proposed AXSM sale?

The broker listed is Charles Schwab & Co., Inc., 3000 Schwab Way, Westlake TX 76262.

When and how were the shares being sold acquired?

The 20,000 shares were acquired on 03/19/2019 by exercise and hold from Axsome Therapeutics, Inc., with payment in cash.

What sales by the same person occurred in the past three months?

Sales listed: 16,694 shares on 08/22/2025 (proceeds $2,004,598.00), and three sales of 20,000 shares on 08/26/2025, 08/27/2025, 08/28/2025 with proceeds $2,400,658.00, $2,446,052.00, and $2,432,004.00 respectively.

Does the Form 144 disclose any material nonpublic information about Axsome?

No. The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.